Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

#8482;; the timing of the announcement of clinical results and potential regulatory filings by Baxter Healthcare for BAX 855; the timing of availability of topline overall survival data for the NKTR-102 BEACON study; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and app
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  BioLife Solutions, Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues ("BioLife" or the "Company"), announced that the ... Conference. The Company is scheduled to present ... 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, ... announced a peer-reviewed publication of the results of ... RGN-259 (RegeneRx,s preservative-free eye drops) for the treatment ... adverse environment (CAE ® ) model.  The exploratory ... results, which were previously disseminated by the Company ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... Henry Schein, Inc. (Nasdaq: HSIC ), the ... practitioners, announced today that it will release its third quarter ... October 29, 2010, and will provide a live webcast of ... 10:00 a.m. Eastern Daylight Time. Speakers on the call will ...
... French genome engineering specialist, today published its consolidated financial ... increased 25% over H1 2009, expenditure increased 50% and ... in cash reserves. During the first half ... new agreements (with BASF Plant Science, Boehringer Ingelheim), published ...
Cached Medicine Technology:Henry Schein to Webcast Third Quarter 2010 Conference Call Friday, October 29, at 10:00 a.m. EDT 2Cellectis Publishes Its Financial Statement for the First Half of 2010 2Cellectis Publishes Its Financial Statement for the First Half of 2010 3
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ProFlare ... simple as dragging and dropping footage into the FCPX timeline ... , Including over 80 stunning flares, ProFlare 5K Prism ... the ultimate bundle for adding prismatic refractions to any video. ... movie files designed for Final Cut Pro X, but are ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood ... designing with reclaimed wood, introducing their latest reclaimed wood ... Their newest offerings, Vat 35, Reclaimed Teak , ... to America's largest design event. , “Designers, architects, builders, ... anxious to see and feel the variety of wood ...
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... May 22, 2015 Omar Ahmad Barrada, ... to participate in the 2015 Congress of Future Medical ... as a gathering of “America’s highest achieving high school ... of healthcare, set new goals and learn better study ... live surgery, during which we can ask the surgeons ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... for its treatment by the FDA, following a clinical ... Taxotere survived an average of 11.4 months without disease ... ,The drug will be used before radiation, ... advanced squamous cell head and neck cancer. Its side ...
... human gene therapy for Parkinson's disease has given the green ... reducing symptoms for patients,// according to the reports of two ... yesterday and last week the researchers reported that each of ... trials received some benefit and none had significant side effects. ...
... A new experimental vaccine developed by scientists in the US ... help prevent the disease that has kills one million// people ... S and developed by Walter Reed Army Institute of Research ... percent for up to 18 months after vaccination among children ...
... a computer-driven system can significantly reduce the duration ... the intensive// care unit (ICU), as compared with ... ,The study, which was conducted in five medical-surgical ... appears in the second issue for October 2006 ...
... in the October issue of the Journal of the American ... elderly women who have not received// up to the mark ... compared to the younger lot. , ,David Litvak ... colleagues studied the records of 354 breast cancer patients who ...
... turning out to be a big challenge for law enforcement officials ... from the last decade, lock-ups /arrests due to possession of ice ... ,Yet, despite this entire hullabaloo, scientists have not been able ... that is still unclear about the link between this drug and ...
Cached Medicine News:Health News:Gene therapy Beneficial in Parkinson's Disease 2Health News:Gene therapy Beneficial in Parkinson's Disease 3Health News:Computer-Driven System Reduces Patient Mechanical Ventilation Time Significantly 2
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... complete line of flowmeters, available in ... . They are all available in ... suit your application. With color coded ... gas in use, the Amvex Flowmeter ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line of ... and CO 2 . They are ... calibrations to best suit your application. ... specific to the gas in use, ...
Medicine Products: